The drug used for the treatment of opioid addiction – buprenorphine, commonly known as Suboxone – had been sold exclusively by Reckitt-Benckiser, a British pharmaceutical company, until its patent ran out in 2012. Since then, several pharmaceutical companies have rushed into the growing market to treat opioid addiction.
Braeburn Pharmaceuticals and Titan Pharmaceuticals (NASDAQ: TTNP) are joining the mix, as they jointly announced today that the Food and Drug Administration (FDA) Advisory Committee will review its new drug, Probuphine, on January 12, 2016.
Probuphine is an investigational implant that gives patients a steady dose of buprenorphine, an opioid addiction treatment drug, for up to 6 months via tiny rods about the size of a matchstick, which are implanted under the skin in the upper arm. It is intended to promote patient compliance as compared to oral formulations of buprenorphine sold under the brand name Suboxone.
To read the full article, please visit The National Pain Report at: http://nationalpainreport.com/implantable-version-of-suboxone-for-opioid-addiction-to-get-fda-review-8828649.html